Expand SVRA Menu
SVRA MENU

SVRA Stock Posts


SVRA #Savara stock increases 4.0% after hours.

After Hours Gainer

SVRA Savara5.53-0.19-3.3%

After Hours:5.75+0.22 (+4.0%)

Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Business WireFri, 20-Feb 4:15 PM
Something to keep an eye on: Mostly large institutional traders are showing a short build up in $SVRA. Net option volume delta is -128 K!
Unusual Option Volume

SVRA Savara4.68+0.51 (+12.2%)

Savara trades 3,329 contracts. The highest volume is in the 19-Dec-25 5 calls, which is 6.8% above the current price.
View Details...
SVRA #Savara stock declines -36.3% in premarket,

Premarket Decliner

SVRA Savara2.84-0.09-3.1%

Premarket:1.81-1.03 (-36.3%)

Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP)

Business WireTue, 27-May 8:05 AM
Unusual Option Volume

SVRA Savara4.06+0.26 (+6.8%)

Savara trades 4,869 contracts. The company has the following event: Clinical Trial Update Investor Call on Jun 26, 2024. News: Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
View Details...

SVRA 4.12+0.32 (+8.4%)Savara
Load Earlier Posts
Market Data Delayed 15 Minutes